Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non-small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)

被引：0
|
作者：
Smit, E. F. [1 ]
Felip, E. [2 ]
Uprety, D. [3 ]
Nagasaka, M. [4 ]
Nakagawa, K. [5 ]
Paz-Ares, L. [6 ]
Pacheco, J. [7 ]
Li, B. T. [8 ]
Planchard, D. [9 ]
Baik, C. S. [10 ]
Goto, Y. [11 ]
Murakami, H. [12 ]
Pereira, K. M. C. [13 ]
Taguchi, A. [14 ]
Kogo, M. [14 ]
Kuwahara, Y. [13 ]
Zou, M. [13 ]
Feng, W. [13 ]
Tsuchihashi, Z. [13 ]
Janne, P. A. [15 ]
机构：
[1] Univ Med Ctr, Dept Pulm Dis, Leiden, Netherlands
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Barbara Ann Karmanos Canc Inst, Med Oncol, Detroit, MI USA
[4] Univ Calif Irvine, Sch Med, Med, Orange, CA USA
[5] Kindai Univ Hosp, Med Oncol, Osaka, Japan
[6] Clin Univ Navarra, Med Oncol, Madrid, Spain
[7] Univ Colorado, Ctr Canc, Internal Med, Med Oncol, Aurora, IL USA
[8] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[9] Gustave Roussy, Med Oncol, Villejuif, France
[10] Univ Washington, Med Oncol, Seattle, WA USA
[11] Natl Canc Ctr, Thorac Oncol Dept, Tokyo, Japan
[12] Shizuoka Canc Ctr, Med Oncol, Shizuoka, Japan
[13] Daiichi Sankyo Inc, Oncol, Basking Ridge, NJ USA
[14] Daiichi Sankyo Co Ltd, Oncol, Tokyo, Japan
[15] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2875
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151P
引用
收藏
页码：S241 / S242
页数：2
相关论文
共 50 条
  • [31] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [32] Effects of trastuzumab (H) and chemotherapy on circulating HER2 extracellular domain (ECD) in patients with metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC)
    Leyland-Jones, B
    Marty, M
    Baselga, J
    Gatzemeier, U
    Barton, C
    Lennon, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 19S - 19S
  • [33] A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)
    Planchard, D.
    Yang, J. C-H.
    Brahmer, J. R.
    Ragone, A.
    Chen, J.
    Liu, F.
    Saggese, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S798 - S798
  • [34] Real world data on Trastuzumab Deruxtecan (T-DXd) induced Interstitial Lung disease (ILD) in HER2 positive metastatic breast cancer patients at the Kent Oncology Centre
    Mohammed, S.
    Moss, C.
    Harper-Wynne, C.
    CLINICAL ONCOLOGY, 2025, 38
  • [35] Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
    Smit, E.
    Nakagawa, K.
    Nagasaka, M.
    Felip, E.
    Goto, Y.
    Li, B.
    Pacheco, J.
    Murakami, H.
    Barlesi, F.
    Saltos, A.
    Perol, M.
    Udagawa, H.
    Saxena, K.
    Shiga, R.
    Guevara, F.
    Acharyya, S.
    Shahidi, J.
    Planchard, D.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S173
  • [36] Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) patients from East Asia.
    Ahn, Beung-Chul
    Loong, Herbert H. F.
    Siu-Hong, Oscar
    Lee, Michelle Mei Lin
    Oslen, Steven R.
    Cho, Byoung Chul
    Mok, Tony S. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab
    Janjigian, Yelena Yuriy
    Riches, Jamie Cathleen
    Ku, Geoffrey Yuyat
    Imtiaz, Tooba
    Capanu, Marinela
    Chou, Joanne F.
    Kelsen, David Paul
    Ilson, David H.
    Berger, Michael F.
    Vakiani, Efsevia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC
    Cappuzzo, F
    Gregorc, V
    Rossi, E
    Cancellieri, A
    Magrini, E
    Paties, CT
    Ceresoli, G
    Lombardo, L
    Bartolini, S
    Calandri, C
    De Rosa, M
    Villa, E
    Crinò, L
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) : 2658 - 2663
  • [39] Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
    Dieras, Veronique
    Deluche, Elise
    Lusque, Amelie
    Pistilli, Barbara
    Bachelot, Thomas
    Pierga, Jean-Yves
    Viret, Frederic
    Levy, Christelle
    Salabert, Laura
    Le Du, Fanny
    Dalenc, Florence
    Jouannaud, Christelle
    Venat-Bouvet, Laurence
    Jacquin, Jean-Philippe
    Durando, Xavier
    Petit, Thierry
    Oukhatar, Celine Mahier -Ait
    Filleron, Thomas
    Mosele, Maria Fernanda
    Lacroix-Triki, Magali
    Ducoulombier, Agnes
    Andre, Fabrice
    CANCER RESEARCH, 2022, 82 (04)
  • [40] Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
    Chan, O. S. H.
    Cheung, G. Y.
    Lee, M. M. L.
    Olsen, S.
    ANNALS OF ONCOLOGY, 2019, 30
12345